APOE ε4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics

Neurology

Volumn 73, Issue 24, 2009, Pages 2052-2053

  Kaufer, Dan ^a   Gandy, Sam ^b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; BAPINEUZUMAB; IMMUNOGLOBULIN G; PLACEBO; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANXIETY; BACKACHE; CLINICAL TRIAL; COGNITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EDEMA; EDITORIAL; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOGENOMICS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VASOGENIC EDEMA; VOMITING; DRUG EFFECT; GENETICS; HETEROZYGOTE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; NOTE; PSYCHOLOGICAL ASPECT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIBODIES, MONOCLONAL; APOLIPOPROTEIN E4; COGNITION; HETEROZYGOTE; HUMANS; INJECTIONS, INTRAVENOUS; TREATMENT OUTCOME;

EID: 73349117170     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181c6784a     Document Type: Editorial

References (10)

1. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995;92:12260-12264.
2. Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol 1996;148: 2083-2095.
3. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177.
4. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54.
5. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061-2070.
6. Petrushina I, Ghochikyan A, Mktrichyan M, et al. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci 2007;27:12721-12731.
7. Relkin NR, Mujalli DM, Shenoy SA, et al. IVIg contains antibodies against oligomers and fibrils of beta amyloid. Alzheimer Dementia J Alzheimer Assoc 2007;3:S196.
8. Risner ME, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006;6:246-254.
9. Reger MA, Henderson ST, Hale C, et al. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging 2004;3:311-314.
10. Zhong N, Weisgraber KH. Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. J Biol Chem 2009;284:6027-6031.